Literature DB >> 21269287

Remission and relapse in a drug-resistant epilepsy population followed prospectively.

Brian Callaghan1, Malka Schlesinger, William Rodemer, John Pollard, Dale Hesdorffer, W Allen Hauser, Jacqueline French.   

Abstract

PURPOSE: We investigated the cumulative probability of seizure remission and relapse in an adult population with drug-resistant epilepsy and frequent seizures. In addition, we determined clinical predictors of remission and relapse in this population.
METHODS: IN 2003, we identified 246 patients at a single center with drug-resistant epilepsy defined as at least one seizure per month and failure of at least two antiepileptic drugs. These patients were followed prospectively (cohort design). We examined the cumulative probability of seizure remission and relapse in this population using Kaplan-Meier methodology. Clinical predictors of remission and relapse were also evaluated using Cox regression analysis. KEY
FINDINGS: The estimated cumulative probability of 12-month seizure remission was 34.6% at 7 years in the entire population and 33.4% when limited to those without surgery. The risk for relapse after a 12-month period of seizure remission was 71.2% at 5 years. Negative predictors of seizure remission included developmental delay, symptomatic generalized epilepsy syndrome, duration of intractability, and number of antiepileptic drugs failed. Localization-related epilepsy was the only negative predictor of relapse. SIGNIFICANCE: Among patients with drug-resistant epilepsy, 5% per year enter seizure remission even with a follow-up of 6 years. However, a substantial proportion of these patients relapse after the first year following a remission. The large proportion of patients entering a significant remission gives these patients hope; however, caution should be advised when discussing the likelihood of future seizures. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269287      PMCID: PMC3147304          DOI: 10.1111/j.1528-1167.2010.02929.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  21 in total

1.  A follow-up study of intractable seizures in childhood.

Authors:  P R Huttenlocher; R J Hapke
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

2.  Early identification of refractory epilepsy.

Authors:  P Kwan; M J Brodie
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

3.  The prognosis for seizure control in newly diagnosed epilepsy.

Authors:  R D Elwes; A L Johnson; S D Shorvon; E H Reynolds
Journal:  N Engl J Med       Date:  1984-10-11       Impact factor: 91.245

4.  Remission of seizures and predictors of intractability in long-term follow-up.

Authors:  M Sillanpää
Journal:  Epilepsia       Date:  1993 Sep-Oct       Impact factor: 5.864

5.  Remission of seizures and relapse in patients with epilepsy.

Authors:  J F Annegers; W A Hauser; L R Elveback
Journal:  Epilepsia       Date:  1979-12       Impact factor: 5.864

6.  Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.

Authors:  Patrick Kwan; Alexis Arzimanoglou; Anne T Berg; Martin J Brodie; W Allen Hauser; Gary Mathern; Solomon L Moshé; Emilio Perucca; Samuel Wiebe; Jacqueline French
Journal:  Epilepsia       Date:  2009-11-03       Impact factor: 5.864

Review 7.  The consequences of uncontrolled epilepsy.

Authors:  Michael R Sperling
Journal:  CNS Spectr       Date:  2004-02       Impact factor: 3.790

8.  Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Collaborative Group for the Study of Epilepsy.

Authors: 
Journal:  Epilepsia       Date:  1992 Jan-Feb       Impact factor: 5.864

9.  Remission of epilepsy: results from the National General Practice Study of Epilepsy.

Authors:  O C Cockerell; A L Johnson; J W Sander; Y M Hart; S D Shorvon
Journal:  Lancet       Date:  1995-07-15       Impact factor: 79.321

10.  EEG and other early predictors of epilepsy remission: a community study.

Authors:  S Q Shafer; W A Hauser; J F Annegers; D W Klass
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

View more
  38 in total

1.  Confusing placebo effect with natural history in epilepsy: A big data approach.

Authors:  Daniel M Goldenholz; Robert Moss; Jonathan Scott; Sungyoung Auh; William H Theodore
Journal:  Ann Neurol       Date:  2015-07-29       Impact factor: 10.422

2.  Drug-Resistant Epilepsy: Is it Really Sometimes RRMS (Relapsing-Remitting Multiple Seizures)?

Authors:  David Spencer
Journal:  Epilepsy Curr       Date:  2017 Jan-Feb       Impact factor: 7.500

3.  Are we too pessimistic about drug-resistant epilepsy?

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2012-11       Impact factor: 7.500

4.  [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].

Authors:  A Strzelczyk; H M Hamer
Journal:  Nervenarzt       Date:  2016-04       Impact factor: 1.214

5.  Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study.

Authors:  Zhibin Chen; Martin J Brodie; Danny Liew; Patrick Kwan
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

Review 6.  Response to placebo in clinical epilepsy trials--Old ideas and new insights.

Authors:  Daniel M Goldenholz; Shira R Goldenholz
Journal:  Epilepsy Res       Date:  2016-02-10       Impact factor: 3.045

7.  Neurology's Silent Killer: Drug-Resistant Epilepsy.

Authors:  Lara Jehi
Journal:  Epilepsy Curr       Date:  2016 Jul-Aug       Impact factor: 7.500

Review 8.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 9.  Pharmacoresistance and the role of surgery in difficult to treat epilepsy.

Authors:  Samuel Wiebe; Nathalie Jette
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

Review 10.  Anti-epileptogenic clinical trial designs in epilepsy: issues and options.

Authors:  Dieter Schmidt; Daniel Friedman; Marc A Dichter
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.